Prelude Therapeutics (PRLD) News Today $0.90 +0.03 (+3.67%) Closing price 04:00 PM EasternExtended Trading$0.90 0.00 (-0.10%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challengesMay 28 at 11:23 AM | investing.comPrelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical ProgramsMay 10, 2025 | msn.comPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comPrelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025May 5, 2025 | msn.comBoxer Capital Management LLC Purchases New Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)Boxer Capital Management LLC bought a new stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,708,187 shares of the company's stock, valued at approximaMay 4, 2025 | marketbeat.comRenaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD)Renaissance Technologies LLC grew its position in Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) by 222.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 634,500 shares of the companMay 4, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Prelude Therapeutics (NASDAQ:PRLD)JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 target price on shares of Prelude Therapeutics in a research report on Tuesday.May 1, 2025 | marketbeat.comPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comPrelude Therapeutics (PRLD) Projected to Post Quarterly Earnings on TuesdayPrelude Therapeutics (NASDAQ:PRLD) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-prelude-therapeutics-incorporated-stock/)May 1, 2025 | marketbeat.comPrelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer TherapiesApril 30, 2025 | msn.comPrelude Announces Presentations at 2025 AACR Annual MeetingApril 25, 2025 | globenewswire.comPrelude Therapeutics Founder Acquires 28% More StockMarch 29, 2025 | finance.yahoo.comPrelude Therapeutics CEO buys $467K in common stockMarch 28, 2025 | markets.businessinsider.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in StockMarch 28, 2025 | insidertrades.comPrelude Therapeutics stock surges on insider buyingMarch 27, 2025 | investing.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 SharesMarch 15, 2025 | insidertrades.comPrelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsMarch 14, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)March 12, 2025 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)March 12, 2025 | markets.businessinsider.comPrelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)March 10, 2025 | markets.businessinsider.comPrelude Therapeutics sees cash runway into 2Q26March 10, 2025 | markets.businessinsider.comPrelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025March 10, 2025 | globenewswire.comPrelude Therapeutics to Present at Barclays Global Healthcare ConferenceMarch 6, 2025 | msn.comPrelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare ConferenceMarch 5, 2025 | globenewswire.comInsider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires 10,000 Shares of StockJanuary 3, 2025 | insidertrades.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Acquires $12,000.00 in StockPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CEO Krishna Vaddi bought 10,000 shares of the business's stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $1.20 per share, with a total value of $12,000.00. Following the purchase, the chief executive officer now directly owns 137,553 shares of the company's stock, valued at approximately $165,063.60. This represents a 7.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.January 2, 2025 | marketbeat.comAndrew Combs Acquires 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) StockDecember 27, 2024 | insidertrades.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Acquires $82,200.00 in StockPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) insider Andrew Combs purchased 60,000 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $1.37 per share, with a total value of $82,200.00. Following the transaction, the insider now directly owns 377,623 shares in the company, valued at approximately $517,343.51. This trade represents a 18.89 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.December 26, 2024 | marketbeat.comKrishna Vaddi Bought 4.9% More Shares In Prelude TherapeuticsDecember 22, 2024 | uk.finance.yahoo.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Bryant David Lim Buys 25,000 SharesDecember 21, 2024 | insidertrades.comFueling growth: The Innovation Space powers breakthroughs in life sciences, clean technologies, and advanced materialsDecember 20, 2024 | bizjournals.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Acquires $22,750.00 in StockPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CFO Bryant David Lim purchased 25,000 shares of Prelude Therapeutics stock in a transaction dated Thursday, December 19th. The stock was bought at an average price of $0.91 per share, with a total value of $22,750.00. Following the acquisition, the chief financial officer now directly owns 27,400 shares of the company's stock, valued at approximately $24,934. This trade represents a 1,041.67 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.December 20, 2024 | marketbeat.comKrishna Vaddi Buys 100,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) StockPrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CEO Krishna Vaddi purchased 100,000 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The stock was acquired at an average price of $0.93 per share, for a total transaction of $93,000.00. Following the purchase, the chief executive officer now owns 1,167,275 shares of the company's stock, valued at approximately $1,085,565.75. This represents a 9.37 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.December 20, 2024 | marketbeat.comPrelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527December 13, 2024 | msn.comPrelude Therapeutics (PRLD) Gets a Sell from Morgan StanleyDecember 12, 2024 | markets.businessinsider.comPrelude Therapeutics presents first interim data from trial of PRT2527December 12, 2024 | markets.businessinsider.comPrelude Therapeutics: Promising Clinical Advancements and Strong Financial Position Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comPrelude Therapeutics price target lowered to $4 from $7 at JMP SecuritiesDecember 11, 2024 | markets.businessinsider.comPrelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesDecember 11, 2024 | globenewswire.comPrelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitNovember 27, 2024 | globenewswire.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest UpdatePrelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,940,000 shares, a growth of 18.1% from the October 15th total of 2,490,000 shares. Currently, 13.9% of the shares of the company are sold short. Based on an average trading volume of 340,700 shares, the short-interest ratio is presently 8.6 days.November 17, 2024 | marketbeat.comPrelude Therapeutics (PRLD) Receives a Sell from BarclaysNovember 9, 2024 | markets.businessinsider.comPrelude Therapeutics Reports Q3 2024 Results and Clinical ProgressNovember 9, 2024 | msn.comPrelude Therapeutics' (PRLD) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comPrelude Therapeutics: Promising Developments and Strategic Collaborations Drive Buy RatingNovember 7, 2024 | markets.businessinsider.comPrelude Therapeutics Shows Strong Q3 2024 Financial ResultsNovember 7, 2024 | markets.businessinsider.comPrelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | finance.yahoo.comOptimism in Prelude Therapeutics: Buy Rating Backed by Promising PRT3789 Trial ResultsOctober 28, 2024 | markets.businessinsider.comPrelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Prelude Therapeutics in a research note on Monday.October 28, 2024 | marketbeat.comPrelude Therapeutics price target lowered to $1 from $3 at BarclaysOctober 27, 2024 | markets.businessinsider.com Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address PRLD Media Mentions By Week PRLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRLD News Sentiment▼1.360.88▲Average Medical News Sentiment PRLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRLD Articles This Week▼21▲PRLD Articles Average Week Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tango Therapeutics News Innate Pharma News Y-mAbs Therapeutics News UroGen Pharma News SOPHiA GENETICS News CARGO Therapeutics News SELLAS Life Sciences Group News Inhibrx News Tiziana Life Sciences News Organigram News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRLD) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRLD Stock Free PRLD Stock Alerts